Navigation Links
Battelle Selects Xie to Develop Biomarker Services
Date:6/25/2008

COLUMBUS, Ohio, June 25 /PRNewswire-USNewswire/ -- Battelle is strengthening its customer-focused biomarker services portfolio to pharmaceutical, biotechnology, medical device, and government clients, and Kevin Xie will lead those efforts as Battelle's Vice President of Biomarker Services.

Battelle offers a suite of biomarker services, including biomarker discovery, qualification, and validation services to help our clients better define molecular mechanisms of diseases, toxicity, and therapeutic responses.

Xie brings an impressive background to Battelle. He has expertise in pharmaceutical, medical device and diagnostics spanning a number of therapeutic areas including oncology, immunology and infectious diseases.

He has been the director and head of global business development of specialty pharmaceuticals at Boehringer Ingelheim Corp. for the last two years. For four years prior to that, Xie was the director and head of global business development for diabetes care for Bayer Healthcare. At Vertex Pharmaceuticals from 2000-02, he was the director of licensing and business development. For the three years prior to that, Xie was the director of business development and strategic planning at Baxter Healthcare.

Xie earned a Ph.D. in molecular biology at Yale University as well as an MBA in finance and strategy. He earned bachelor's and master's degrees from Fudan University in Shanghai, China.

"We are pleased to hire Kevin not only because we believe he is a quality person but because his diverse background made him the perfect candidate for the job," said Barbara Kunz, President of Battelle's Health and Life Sciences Global Business. "The mix of business, biology, and pharmacological work in his career will make him successful here."

Battelle's Global Health and Life Sciences Global Business delivers a comprehensive set of R&D services to solve complex challenges for government health agencies and medical device, biotechnology, and pharmaceutical firms. Including its national laboratories, Battelle oversees over $200 million annually in health and life sciences research and development contributing to advances in medical devices, pharmaceuticals, public health, and next-generation diagnostics and therapeutics.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. It advances scientific discovery and application by conducting $4 billion in global R&D annually through contract research, laboratory management, and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 20,400 employees in more than 120 locations worldwide, including seven national laboratories which Battelle manages or co-manages for the U.S. Department of Energy and the U.S. Department of Homeland Security.

Battelle also is one of the nation's leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science and math education.

Contact National Media Relations Manager Katy Delaney at (410) 306-8638 or delaneyk@battelle.org or T.R. Massey, Media Relations Specialist, at (614) 424-5544 or masseytr@battelle.org for more information.


'/>"/>
SOURCE Battelle
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle
2. MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector
3. Battelle Collaborating With Korean Partners to Advance Energy Efficiency and Health and Life Sciences Initiatives in Korea
4. Battelle Earns 2008 Presidential Green Chemistry Award
5. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
6. Detroit Department of Health and Wellness Promotion Selects Netsmart Technologies Public Health Software
7. E-Rad Solutions Selects Compressus Enterprise Systems Integration Technology to Fuel Entry Into Teleradiology Market
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. GeneSeek Selects the British Midlands as Base for New UK/European Operations
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):